MX2023007288A - Polipeptidos y usos de los mismos. - Google Patents

Polipeptidos y usos de los mismos.

Info

Publication number
MX2023007288A
MX2023007288A MX2023007288A MX2023007288A MX2023007288A MX 2023007288 A MX2023007288 A MX 2023007288A MX 2023007288 A MX2023007288 A MX 2023007288A MX 2023007288 A MX2023007288 A MX 2023007288A MX 2023007288 A MX2023007288 A MX 2023007288A
Authority
MX
Mexico
Prior art keywords
polypeptides
pramlintide
analogues
moieties
seq
Prior art date
Application number
MX2023007288A
Other languages
English (en)
Spanish (es)
Inventor
Maria Aleksandra Bednarek
Sivaneswary Genapathy
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of MX2023007288A publication Critical patent/MX2023007288A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/31Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2023007288A 2020-12-16 2021-12-15 Polipeptidos y usos de los mismos. MX2023007288A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063125996P 2020-12-16 2020-12-16
PCT/EP2021/086034 WO2022129254A1 (en) 2020-12-16 2021-12-15 Polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
MX2023007288A true MX2023007288A (es) 2023-07-03

Family

ID=79287870

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007288A MX2023007288A (es) 2020-12-16 2021-12-15 Polipeptidos y usos de los mismos.

Country Status (16)

Country Link
US (3) US12371464B2 (enExample)
EP (1) EP4263586A1 (enExample)
JP (1) JP7767428B2 (enExample)
KR (1) KR20230120134A (enExample)
CN (1) CN116685599A (enExample)
AR (1) AR124391A1 (enExample)
AU (2) AU2021399076B2 (enExample)
CA (1) CA3204296A1 (enExample)
CL (1) CL2023001719A1 (enExample)
CO (1) CO2023009066A2 (enExample)
CR (1) CR20230311A (enExample)
EC (1) ECSP23052600A (enExample)
IL (1) IL303578A (enExample)
MX (1) MX2023007288A (enExample)
TW (1) TW202241933A (enExample)
WO (1) WO2022129254A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12371464B2 (en) 2020-12-16 2025-07-29 Medimmune Limited Polypeptides and uses thereof
IL304214B2 (en) 2021-01-20 2025-01-01 Viking Therapeutics Inc Compositions and methods for treating metabolic and liver disorders
KR102873595B1 (ko) 2021-09-15 2025-10-22 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 장애의 치료를 위한 조성물 및 방법
US12116388B2 (en) 2022-12-22 2024-10-15 Novo Nordisk A/S Amylin receptor agonists
IL322661A (en) * 2023-02-10 2025-10-01 Hangzhou Sciwind Biosciences Co Ltd Polypeptide and its history, composition containing them and their use
JP7755031B2 (ja) 2023-11-30 2025-10-15 ノヴォ ノルディスク アー/エス Glp-1、gip、およびアミリン受容体の三重作動薬
WO2025147628A2 (en) * 2024-01-05 2025-07-10 Indiana University Research And Technology Corporation Dual amylin calcitonin receptor agonists
WO2025242620A1 (en) 2024-05-20 2025-11-27 Medimmune Limited Polypeptide combinations and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004051014A1 (de) * 2004-10-20 2006-04-27 Rwth Aachen Chemisch modifizierte Peptidanaloga
EP1996617A2 (en) * 2006-03-15 2008-12-03 Novo Nordisk A/S Amylin derivatives
EP2036923A1 (en) * 2007-09-11 2009-03-18 Novo Nordisk A/S Improved derivates of amylin
CN102197049B (zh) * 2008-10-21 2015-03-25 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
US9205135B2 (en) * 2009-09-22 2015-12-08 University Of Miami Podocyte pH modulation and uses thereof
WO2013059336A1 (en) * 2011-10-18 2013-04-25 Amylin Pharmaceuticals, Llc Amylin-calcitonin chimeric peptides conjugated to duration enchancing moieties
MX2016007407A (es) * 2013-12-13 2016-12-12 Medimmune Ltd Peptidos resistentes a proteasa.
JP6730278B2 (ja) * 2014-11-27 2020-07-29 ノヴォ ノルディスク アー/エス Glp−1誘導体及びその使用
KR20210091705A (ko) * 2018-10-11 2021-07-22 인타르시아 세라퓨틱스 인코포레이티드 인간 아밀린 유사체 폴리펩타이드 및 사용 방법
WO2020225781A1 (en) * 2019-05-08 2020-11-12 Auckland Uniservices Limited Peptide conjugate amylin agonists and uses thereof
US12371464B2 (en) 2020-12-16 2025-07-29 Medimmune Limited Polypeptides and uses thereof

Also Published As

Publication number Publication date
ECSP23052600A (es) 2023-08-31
AR124391A1 (es) 2023-03-22
AU2021399076B2 (en) 2024-07-11
CL2023001719A1 (es) 2024-01-26
US20220204580A1 (en) 2022-06-30
CN116685599A (zh) 2023-09-01
AU2024227071A1 (en) 2024-10-24
JP2023554046A (ja) 2023-12-26
AU2021399076A1 (en) 2023-07-27
US12371464B2 (en) 2025-07-29
US20240067693A1 (en) 2024-02-29
KR20230120134A (ko) 2023-08-16
IL303578A (en) 2023-08-01
AU2021399076A9 (en) 2024-07-18
US20250289860A1 (en) 2025-09-18
CO2023009066A2 (es) 2023-07-10
CR20230311A (es) 2023-09-01
CA3204296A1 (en) 2022-06-23
TW202241933A (zh) 2022-11-01
WO2022129254A1 (en) 2022-06-23
EP4263586A1 (en) 2023-10-25
JP7767428B2 (ja) 2025-11-11

Similar Documents

Publication Publication Date Title
MX2023007288A (es) Polipeptidos y usos de los mismos.
EP4442816A3 (en) Mutated glycoprotein of vesicular stomatitis virus
IL232501A0 (en) Stable analogs of medicinal peptides and polypeptides
MXPA04001982A (es) Factor ix modificado.
EP4467650A3 (en) Scaffold proteins
IN2014CN02050A (enExample)
SA522433360B1 (ar) L-أَسْباراجيناز مُعدل
BG103091A (en) Shortened soluble receptors of type i & ii of the tumour necrotizing factor
WO2007056362A3 (en) Glucagon analogs exhibiting physiological solubility and stability
MY209410A (en) Recombinant protein variants
MX2022009515A (es) Variantes de alfa-amilasa y polinucleotidos que las codifican.
IL173158A0 (en) Polypeptide having an improved cytosine deaminase activity
WO2018215525A8 (en) Mic-1 compounds and uses thereof
PH12023552771A1 (en) Compositions comprising a variant polypeptide and uses thereof
MX2023011400A (es) Composiciones inmunogenicas.
BG106008A (en) Novel lhrh antagonists with improved solubility characteristics
MX2024007864A (es) Polipeptidos lilrb y usos de los mismos.
EP4011905A3 (en) Compstatin analogs with increased solubility and improved pharmacokinetic properties
SI2076532T1 (sl) Derivati citokina
EP4282960A3 (en) Modified lipase and use thereof
TW200722436A (en) A peptide-immunoglobulin-conjugate
CR20240532A (es) Péptido con actividad antimicrobiana
DE50213015D1 (de) Lipase-varianten
WO2022170216A3 (en) Omni 90-99, 101, 104-110, 114, 116, 118-123, 125, 126, 128, 129, and 131-138 crispr nucleases
MY126118A (en) Somatostatin analogs for the treatment of cancer